N4 Pharma PLC Holding(s) in Company
19 Junio 2024 - 1:00AM
RNS Regulatory News
RNS Number : 9577S
N4 Pharma PLC
19 June 2024
TR-1: Standard form for notification
of major holdings
|
|
|
|
1a.
Identity of the issuer or the underlying issuer of existing shares
to which voting rights are attachedii:
|
N4 Pharma
PLC
|
|
1b.
Please indicate if the issuer is a non-UK
issuer (please mark with an
"X" if appropriate)
|
|
Non-UK issuer
|
|
|
2.
Reason for the notification (please
mark the appropriate box or boxes with an "X")
|
|
An acquisition or disposal of voting
rights
|
|
|
An acquisition or disposal of
financial instruments
|
|
|
An event changing the breakdown of
voting rights
|
X
|
|
Other (please
specify)iii:
|
|
|
3.
Details of person subject to the notification
obligationiv
|
|
Name
|
DAVID FARRIER
|
|
City and country of registered office
(if applicable)
|
UK
|
|
4.
Full name of shareholder(s) (if
different from 3.)v
|
|
Name
|
|
|
City and country of registered office
(if applicable)
|
|
|
5.
Date on which the threshold was crossed or
reachedvi:
|
13 June 2024
|
|
6.
Date on which issuer notified
(DD/MM/YYYY):
|
18 June 2024
|
|
7.
Total positions of person(s) subject to the notification
obligation
|
|
|
% of
voting rights attached to shares (total of 8. A)
|
%
of voting rights through
financial instruments
(total of 8.B 1 + 8.B 2)
|
Total of
both in % (8.A + 8.B)
|
Total number of voting rights of
issuervii
|
|
Resulting situation on the date on
which threshold was crossed or reached
|
4.8%
|
|
4.8%
|
394,780,349
|
|
Position of previous notification
(if
applicable)
|
7.0%
|
|
7.0%
|
|
|
|
|
|
|
|
|
| |
|
8.
Notified details of the resulting situation on the date on which
the threshold was crossed or reachedviii
|
|
A:
Voting rights attached to shares
|
|
Class/type of
shares
ISIN code (if possible)
|
Number of voting rightsix
|
% of
voting rights
|
|
Direct
(Art 9 of
Directive 2004/109/EC) (DTR5.1)
|
Indirect
(Art 10
of Directive 2004/109/EC) (DTR5.2.1)
|
Direct
(Art 9 of
Directive 2004/109/EC) (DTR5.1)
|
Indirect
(Art 10
of Directive 2004/109/EC) (DTR5.2.1)
|
|
GB00BYW8QM32
|
18,815,000
|
|
4.8%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8. A
|
18,815,000
|
4.8%
|
|
|
|
|
B 1:
Financial Instruments according to Art. 13(1)(a) of Directive
2004/109/EC (DTR5.3.1.1 (a))
|
|
Type
of financial instrument
|
Expiration
datex
|
Exercise/
Conversion Periodxi
|
Number of voting rights that may be acquired if the instrument
is
exercised/converted.
|
% of
voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8. B 1
|
|
|
|
|
|
|
B 2:
Financial Instruments with similar economic effect according to
Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1
(b))
|
|
Type
of financial instrument
|
Expiration
datex
|
Exercise/
Conversion Period xi
|
Physical or cash
settlementxii
|
Number of voting rights
|
% of
voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8.B.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
9.
Information in relation to the person subject to the notification
obligation (please mark
the
applicable box with an
"X")
|
|
Person subject to the notification
obligation is not controlled by any natural person or legal entity
and does not control any other undertaking(s) holding directly or
indirectly an interest in the (underlying)
issuerxiii
|
X
|
|
Full chain of
controlled undertakings through which the voting rights and/or
the
financial instruments are effectively held starting with the
ultimate controlling natural person or legal
entityxiv (please add additional rows as necessary)
|
|
|
Namexv
|
% of voting rights if it
equals or is higher than the notifiable threshold
|
% of voting rights through
financial instruments if it equals or is higher than the notifiable
threshold
|
Total of both if it equals or
is higher than the notifiable threshold
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10. In case of proxy voting,
please identify:
|
|
Name of the proxy holder
|
NA
|
|
The number and % of voting rights
held
|
NA
|
|
The date until which the voting
rights will be held
|
NA
|
|
|
|
|
11.
Additional informationxvi
|
|
The Company's issued share capital
increased following a Placing announced on 7 June.
|
|
|
|
|
|
| |
|
Place of completion
|
UK
|
|
Date
of completion
|
18 June 2024
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
HOLFFFSIRSITLIS
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
